{'fraction_non_alphanumeric': 0.026119402985074626, 'fraction_numerical': 0.01990049751243781, 'mean_word_length': 5.338582677165355, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Coming of Age of Drug-Susceptibility Testing for Tuberculosis.

Tuberculosis is the leading infectious cause of death worldwide, claiming 1.6 million lives annually.1 Antimicrobial resistance is undermining efforts to curb the global tuberculosis epidemic: among the 10.6 million cases of tuberculosis that occurred in 2016, less than a quarter of the estimated 600,000 patients with multidrug-resistant (MDR) or rifampin-resistant tuberculosis received diagnoses and were treated. Although rollout of the Xpert MTB/RIF molecular test has enabled the rapid detection of resistance to the first-line tuberculosis drug rifampin, a diagnostic test that can accurately determine the complete drug-susceptibility profile of the infecting strain or strains of Mycobacterium tuberculosis would make it . . .